Nitrogen, phosphorus, potassium, calcium and magnesium releasefrom two compressed fertilizers: column experiments

The objective of this work was to study nutrients release from two compressed nitrogen–potassium–phosphorous (NPK) fertilizers. In the Lourizán Forest Center, tablet-type controlled-release fertilizers (CRF) were prepared by compressing various mixtures of fertilizers without covers or binders. We used soil columns (50 cm long and 7.3 cm inner diameter) that were filled with soil from the surface layer (0–20 cm) of an A horizon corresponding to a Cambic Umbrisol. Tablets of two slow-release NPK fertilizers (11–18–11 or 8–8–16) were placed into the soil (within the first 3 cm), and then water was percolated through the columns in a saturated regime for 80 days. Percolates were analyzed for N, P, K+, Ca2+ and Mg2+. These elements were also determined in soil and fertilizer tablets at the end of the trials. Nutrient concentrations were high in the first leachates and reached a steady state when 1426 mm of water had been percolated, which is equivalent to approximately 1.5 years of rainfall in this geographic area. In the whole trial, both tablets lost more than 80% of their initial N, P and K contents. However, K+, Ca2+ and Mg2+ were the most leached, whereas N and P were lost in leachates to a lesser extent. Nutrient release was slower from the tablet with a composition of 8–8–16 than from the 11–18–11 fertilizer. In view of that, the 8–8–16 tablet can be considered more adequate for crops with a nutrient demand sustained over time. At the end of the trial, the effects of these fertilizers on soil chemical parameters were still evident, with a significant increase of pH, available Ca2+, Mg2+, K+, P and effective cation exchange capacity (eCEC) in the fertilized columns, as well as a significant decrease in exchangeable Al3+, reaching values < 0.08 cmol (+) kg−1.S

Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients

SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system—IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII—for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFβ, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the diseaseThis research was coordinated by ProA Capital and Startlite Foundation, Programa de Actividades de I+D de la Comunidad de Madrid en Biomedicina (B2020/MITICAD-CM), Halekulani S.L., MJR; and Universidad de Alcala COVID-19 UAH 2019/00003/016/001/026 and COVID-19 2021-2020/00003/016/001/027Peer reviewe

Identification of recent tuberculosis exposure using QuantiFERON-TB Gold Plus, a multicenter study.

We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune-mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB22TB1 value .0.6 IU ml21 was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2.TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB22TB1 result of .0.6 IU ml21 and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 5.4%, and 17.7% with close, frequent, and sporadic contact had a TB2.TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB22TB1 difference of .0.6 IU ml21 was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection

La dirección y desarrollo de personas

La dirección de personas: una empresa necesita trabajadores. Antes, los contrataba el departamento de personal. Después vinieron los recursos humanos. Ahora, en muchas compañías, estas funciones las hace la dirección de personas. Este libro analiza las funciones básicas de este departamento y las mejoras que aporta al progreso de las empresas.La direcció de persones: una empresa necessita treballadors. Abans, els contractava el departament de personal. Després van venir els recursos humans. Ara, en moltes companyies, aquestes funcions les fa la direcció de persones. Aquest llibre analitza les funcions bàsiques d'aquest departament i les millores que aporta al progrés de les empreses.Managing People: a company needs workers. Before, they were hired by the personnel department. Then came human resources. Now, in many companies, these functions are performed by people management. This book analyses the basic functions of this department and the improvements it brings to the progress of companies

La direcció de persones

La dirección de personas: una empresa necesita trabajadores. Antes, los contrataba el departamento de personal. Después vinieron los recursos humanos. Ahora, en muchas compañías, estas funciones las hace la dirección de personas. Este libro analiza las funciones básicas de este departamento y las mejoras que aporta al progreso de las empresas.La direcció de persones: una empresa necessita treballadors. Abans, els contractava el departament de personal. Després van venir els recursos humans. Ara, en moltes companyies, aquestes funcions les fa la direcció de persones. Aquest llibre analitza les funcions bàsiques d'aquest departament i les millores que aporta al progrés de les empreses.Managing People: a company needs workers. Before, they were hired by the personnel department. Then came human resources. Now, in many companies, these functions are performed by people management. This book analyses the basic functions of this department and the improvements it brings to the progress of companies

El sistema de organización de las entidades financieras en España

Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias Económicas y Empresariales, 198

Cristaluria por sulfadiazina en paciente con nefropatía lúpica

Se estima que el 29% de los pacientes tratados con sulfadiazina pueden desarrollar un fallo renal agudo. Para su diagnóstico debemos recurrir a un análisis del sedimento urinario

A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples

Throughout the pandemic, serological assays have been revealed as crucial for detecting previous exposures to the virus and determining the timing of antibody maintenance after vaccination or natural infection. This study aimed to develop an optimized enzyme-linked immunosorbent assay (ELISA)-based serology, which could be used in case of reagent shortages, such as that occurred in the beginning of this health emergency. As a result, we present a high-sensitive immunoassay for the determination of IgG levels in venous serum samples, using 2 μg/mL antigen (receptor-binding domain of the spike protein S1) for coating the plate and utilizing human samples at a dilution 1:1000. This method showed non-inferiority features versus a commercial kit, is less expensive, and has a higher spectrophotometric range that allows for a better quantification of the antibody titers. The optical density values before and after heating venous serum samples at 56 °C during 30 min was quite similar, showing that heat inactivation can be used to reduce the biohazardous risks while handling samples. Furthermore, we show that finger-stick capillary blood samples can also serve as a suitable source for IgG detection, bypassing the need for serum isolation and being suitable for point-of-care application (Pearson’s coefficient correlation with capillary serum was 0.95, being statistically significant)

Prognosis of 2009 A(H1N1) influenza in hospitalized pregnant women in a context of early diagnosis and antiviral therapy.

Background: Initial reports suggested that novel A(H1N1) influenza virus (2009 A[H1N1]v) infection was significantly more severe in pregnant than in non-pregnant women. In Spain, antiviral therapy was recommended for pregnant women from the beginning of the 2009 pandemic. Methods: The prospective cohort study included consecutive pregnant and non-pregnant women of reproductive age with a proven diagnosis of 2009 A(H1N1)v admitted to any of the 13 participating Spanish hospitals between 12 June and 10 November 2009. Results: In total, 98 pregnant and 112 non-pregnant women with proven 2009 A(H1N1)v hospitalized during the study period were included. Influenza was more severe among non-pregnant patients than pregnant patients with respect to outcomes of both intensive care unit admission (18% versus 2%; P<0.001) and death (5 versus 0; P=0.06). Pregnant women had fewer associated comorbid conditions other than pregnancy (18% versus 44%; P<0.001); they were also admitted earlier than non-pregnant women (median days since onset of symptoms: 2 versus 3; P<0.001) and a higher percentage received early antiviral therapy (41% versus 28%; P=0.03). Neither a multivariate nor a matched cohort analysis found pregnancy to be associated with greater severity than that associated with hospitalized, seriously ill non-pregnant women. Conclusions: 2009 A(H1N1)v influenza was not associated with worse outcomes in hospitalized pregnant women compared with non-pregnant ones of reproductive age in a context of early diagnosis and antiviral therapy.This work was funded by Ministerio de Ciencia e Innovación, Instituto Carlos III, cofinanced by European Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008)